Earnings Summary

Cytokinetics Inc’s revenue fell -99.03% since last year same period to $0.87Mn in the Q2 2023. On a quarterly growth basis, Cytokinetics Inc has generated -81.21% fall in its revenue since last 3-months.

Cytokinetics Inc’s net profit fell -549.03% since last year same period to $-128.64Mn in the Q2 2023. On a quarterly growth basis, Cytokinetics Inc has generated 2.02% jump in its net profits since last 3-months.

Cytokinetics Inc’s net profit margin fell -66500.42% since last year same period to -14837.02% in the Q2 2023. On a quarterly growth basis, Cytokinetics Inc has generated -421.32% fall in its net profit margins since last 3-months.

Cytokinetics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.22 - a -4.27% fall from last quarter’s estimates.

Cytokinetics Inc’s earning per share (EPS) estimates for the current year stand at -1.22.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cytokinetics Inc’s return on assets (ROA) stands at -0.39.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cytokinetics Inc’s return on equity (ROE) stands at -5.72.